Maria C Losada
Overview
Explore the profile of Maria C Losada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin-Loeches I, Shorr A, Kollef M, Du J, Losada M, Paschke A, et al.
Open Forum Infect Dis
. 2023 Jun;
10(6):ofad225.
PMID: 37383243
Background: In the RESTORE-IMI 2 trial, imipenem/cilastatin/relebactam (IMI/REL) was noninferior to piperacillin/tazobactam in treating hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. This post hoc analysis was conducted to determine independent predictors of...
2.
Roberts J, Nicolau D, Martin-Loeches I, DeRyke C, Losada M, Du J, et al.
JAC Antimicrob Resist
. 2023 Mar;
5(2):dlad011.
PMID: 36880088
Objectives: To assess the relationship between renal function and efficacy/safety of imipenem/cilastatin/relebactam for the treatment of hospital-acquired/ventilator-associated pneumonia (HABP/VABP) from RESTORE-IMI 2 and determine the PTA. Methods: Adults with HABP/VABP...
3.
Titov I, Wunderink R, Roquilly A, Gonzalez D, David-Wang A, Boucher H, et al.
Clin Infect Dis
. 2020 Aug;
73(11):e4539-e4548.
PMID: 32785589
Background: Imipenem combined with the β-lactamase inhibitor relebactam has broad antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP)....
4.
Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, et al.
Antimicrob Agents Chemother
. 2016 Aug;
60(10):6234-43.
PMID: 27503659
Relebactam (REL [MK-7655]) is a novel class A/C β-lactamase inhibitor intended for use with imipenem for the treatment of Gram-negative bacterial infections. REL restores imipenem activity against some resistant strains...
5.
Brown J, Daniels S, Bandy D, Ko A, Gammaitoni A, Mehta A, et al.
Clin J Pain
. 2012 Dec;
29(6):492-8.
PMID: 23247002
Objective: To evaluate the analgesic effects of etoricoxib and comparator agents on the second and third days after oral surgery. Methods: There were 588 patients initially randomized to placebo (n=46),...
6.
Daniels S, Bandy D, Christensen S, Boice J, Losada M, Liu H, et al.
Clin J Pain
. 2010 Dec;
27(1):1-8.
PMID: 21188849
Objective: This study was conducted to evaluate the dose range of etoricoxib in acute pain using the postoperative dental pain model further. Methods: This double-blind, randomized controlled study evaluated etoricoxib...
7.
Hepler R, Kelly R, McNeely T, Fan H, Losada M, George H, et al.
Vaccine
. 2005 Nov;
24(10):1501-14.
PMID: 16271808
Infection by Bacillus anthracis is preventable by prophylactic vaccination with several naturally derived and recombinant vaccine preparations. Existing data suggests that protection is mediated by antibodies directed against the protective...